Gijs Verheijden

Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985

Ronald C. Elgersma, Ruud G. E. Coumans, Tijl Huijbregts et al. · Molecular Pharmaceutics · 2015 · 214 citations · Full text

Molecular Biology, Duocarmycin 3B, Pharmaceutical Chemistry +16

Human cartilage glycoprotein‐39 as a candidate autoantigen in rheumatoid arthritis

Gijs Verheijden, Antonius W. M. Rijnders, Ebo Bos et al. · Arthritis & Rheumatism · 1997 · 210 citations · Full text

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

Miranda M.C. van der Lee, Patrick G. Groothuis, Ruud Ubink et al. · Molecular Cancer Therapeutics · 2015 · 208 citations

Breast Oncology, Immunology, Pathology +20

Human cartilage gp‐39+,CD16+ monocytes in peripheral blood and synovium: Correlation with joint destruction in rheumatoid arthritis

Dominique Baeten, Annemieke M. H. Boots, Peter G. A. Steenbakkers et al. · Arthritis & Rheumatism · 2000 · 168 citations

Preclinical Profile of the HER2-Targeting ADC SYD983/SYD985: Introduction of a New Duocarmycin-Based Linker-Drug Platform

Wim H.A. Dokter, Ruud Ubink, Miranda van der Lee et al. · Molecular Cancer Therapeutics · 2014 · 156 citations · Full text

Drug Target, Immunology, Molecular Biology +18